20 Apr 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
16 Mar 2022quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $117 thousand for the period ended 2022-03-31.
1 Apr 2019late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its annual report would be filed late.
14 Nov 2018quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $111 thousand for the period ended 2018-09-30.
4 Sept 2018material agreement● NeutralMajor
On Aug 31, 2018 Zenosense and MIDS Medical (MML), the UK venture where it holds 40%, agreed that an outside investor will fund up to US$1,200,000 in tranches for up to 10.31% of MML; Zenosense's stake will not fall below 30% before a sale of MML. The first tranche is US$300,000 (US$47,000 at signing, US$103,000 by Sept 30 and US$150,000 by Oct 30, 2018) for 2.91%, and later tranches of $300,000, $375,000 and $225,000 are the investor's option through May 31, 2019. The money goes to MML, not Zenosense. Zenosense keeps its control rights, but its percentage in MML will be diluted if the investor takes up the tranches (inference).
20 Aug 2018quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $111 thousand for the period ended 2018-09-30.
14 Aug 2018late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its quarterly report would be filed late.
6 Aug 2018auditor change● Neutral
On Aug 3, 2018 Zenosense replaced its auditor GBH CPAs with Marcum LLP after GBH resigned because it combined its practice with Marcum effective July 1, 2018. GBH's reports for 2016 and 2017 had no adverse opinion but carried a going-concern warning, and there were no disagreements.
21 May 2018quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $123 thousand for the period ended 2018-06-30.
15 May 2018late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its quarterly report would be filed late.
2 Apr 2018late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its annual report would be filed late.
14 Nov 2017quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $144 thousand for the period ended 2017-09-30.
21 Aug 2017quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $144 thousand for the period ended 2017-09-30.
11 Aug 2017late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its quarterly report would be filed late.
19 May 2017quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $161 thousand for the period ended 2017-06-30.
19 May 2017quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $161 thousand for the period ended 2017-06-30.
15 May 2017late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its quarterly report would be filed late.
30 Mar 2017late filing notice▼ Bad
ZENOSENSE, INC. notified the SEC that its annual report would be filed late.
6 Feb 2017material agreement● Neutral
This amendment to the Feb 3 filing corrects one point: it is MML (the joint venture), not Zenosense, that holds the surplus of development cash. The payment dates and optional loan schedule are otherwise unchanged from that filing.
3 Feb 2017capital raising announcement● Neutral
On Jan 31, 2017 Zenosense again moved back its MIDS Medical payments (total still $650,000) to $130,000 by Mar 15, $152,500 by Apr 15 and $75,000 by May 15, 2017, saying there is currently a surplus of development cash and no immediate need for funding; MML also filed a patent application on Jan 18, 2017 for a new 'Magnetic Bridge' detection method. The senior-note holder's optional loans were cut to $160,000, $170,000 and $90,000 on matching dates, after $170,000 had already been lent in Oct and Dec 2016. MML can call payments early on 14 days' notice. The 8-K attributes the surplus to the company, which the 8-K/A of Feb 6 corrects.
7 Dec 2016capital raising announcement● Neutral
On Dec 6, 2016 Zenosense again rescheduled its MIDS Medical payments (same $650,000 total) because MML is exploring an enhancement to its cardiac device technology at minimal cost: $22,500 within 10 days, $152,500 by Jan 31, $130,000 by 'Feb 31' (as written) and $75,000 by Mar 31, 2017. It also changed the optional convertible loans from its senior-note holder to $30,000 (issued that day), $180,000, $140,000 and $100,000 through Mar 31, 2017; the holder had already lent $140,000 on Oct 27, 2016. Terms otherwise match the earlier loans, so further dilution is possible if they convert (inference).
14 Nov 2016quarterly activities report▼ Bad
ZENOSENSE, INC. reported a quarterly net loss of $61 thousand for the period ended 2016-09-30.